

## **Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University**

**- Development of a monoclonal antibody for the treatment  
of Alzheimer's disease -**

**Paris, France – December 3, 2009** – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer's disease.

The anti-Amyloid Beta (ABeta) antibody therapy is a highly attractive approach to prevent and reverse the amyloid plaque formation which may lead to cognitive improvement in patients with Alzheimer's disease. This antibody is planned to enter development at the end of 2009.

*"It's a great pleasure to interact with The Rockefeller University and in particular with Dr. Jeffrey Ravetch, a worldwide expert in the engineering of mAb Fc region and effector functions", declared Marc Cluzel, Executive Vice-President, R&D, sanofi-aventis. "Dr Ravetch discovered the original murine monoclonal antibody targeting the Amyloid Beta peptide, one target which may have a significant positive impact in the management of patients with Alzheimer's disease, which is a public health priority".*

*"I am pleased to contribute with sanofi-aventis to the development of a novel anti-ABeta antibody for the treatment of Alzheimer's Disease" said Dr. Jeffrey Ravetch – Professor and Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University. "The initial studies suggest that this antibody may be an effective means of reducing the progression of this widespread and debilitating disease".*

Under the terms of the agreement, sanofi-aventis will obtain an exclusive worldwide license to develop, manufacture and commercialize the anti-ABeta antibody. The terms of such license are undisclosed.

### **About Alzheimer's disease**

Alzheimer's disease is a progressive, degenerative disease of the brain, which causes thinking and memory to become seriously impaired. It is the most common form of dementia, a syndrome consisting of a number of symptoms that include loss of memory, judgment and reasoning, and changes in mood, behavior and communication abilities. Generally, it is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer's can occur much earlier. In 2009, the reported prevalence of Alzheimer's is 35 million worldwide and to strongly increase in the next decades due to ageing population.

### **About Amyloid Beta (ABeta) and Alzheimer's disease**

One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. Amyloid is a general term for protein fragments that the body produces normally. Amyloid Beta is a protein fragment snipped from an Amyloid Precursor Protein (APP). In a healthy brain, these protein fragments are broken down and eliminated. In Alzheimer's disease, the fragments accumulate to form hard, insoluble plaques.

### **About The Rockefeller University**

The Rockefeller University is a world-renowned center for research and graduate education in the biomedical sciences, chemistry, and physics. Founded by John D. Rockefeller in 1901, the university has been the site of many important scientific breakthroughs. Rockefeller scientists established that DNA is the chemical basis of heredity, discovered blood groups, showed that viruses can cause cancer, founded the modern field of cell biology, and worked out the structure of antibodies. Twenty-three Nobel Prize winners have been associated with the university.

### **About sanofi-aventis**

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

### **Forward Looking Statements**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.*